Worth Watching Stock: AstraZeneca PLC (NYSE:AZN)

$21.50's average target is -5.08% below currents $22.65 stock price. UBS maintained AstraZeneca plc (LON:AZN) on Wednesday, January 11 with "Buy" rating.

Shares of AstraZeneca PLC (NYSE:AZN) [Trend Analysis] runs in leading trade, it plunging -1.00% to traded at $29.62.

There are 1 sell rating, 5 hold ratings, 11 buy ratings on the stock. The company has an average rating of "Buy" and a consensus target price of $34.43.

AstraZeneca PLC (NYSE:AZN) belonging to the Medical sector has declined -1% and closed its last trading session at $29.62. The company's 50 day moving average is GBX 4,633.61 and its 200 day moving average is GBX 4,771.94. The 52 week high for the share price is now at 5505 GBX while the year low stock price is now 3680 GBX. The firm's market cap is GBX 44.26 billion.

The stock was assessed in terms of profitability as current quarter EPS estimate trends showed $0.42 at current month while compared with $0.43 in a month ago. The company had revenue of $5.59 billion for the quarter, compared to the consensus estimate of $5.43 billion. AstraZeneca plc had a return on equity of 34.30% and a net margin of 15.21%. The firm's revenue was down 12.7% compared to the same quarter past year. Holowesko Partners Ltd. now owns 3,221,000 shares of the company's stock valued at $105,842,000 after buying an additional 179,000 shares in the last quarter. There are now 1,269,117,566 shares in issue with the average daily volume traded being 2,936,633. Shareholders of record on Friday, February 17th will be paid a $0.95 dividend.

On 7/29/2016 AstraZeneca plc announced a dividend of $0.44 with an ex dividend date of 8/10/2016 which will be payable on 9/12/2016. This represents a yield of 6.81%. AstraZeneca plc's dividend payout ratio is now 49.64%.

This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another website, it was illegally copied and republished in violation of global trademark & copyright laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/03/08/astrazeneca-plc-azn-stock-rating-reaffirmed-by-cowen-and-company.html. Capital International Investors boosted its stake in AstraZeneca plc by 22.1% in the second quarter. The firm owned 12,260 shares of the company's stock at the end of the third quarter. BlackRock Investment Management LLC boosted its stake in AstraZeneca plc by 73.2% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company's stock valued at $140,000 after buying an additional 103 shares during the last quarter. Yorktown Management & Research Co Inc acquired a new position in Astrazeneca PLC during the third quarter valued at $210,000. Premier Asset Managment LLC now owns 45,760 shares of the company's stock worth $1,503,000 after buying an additional 20,875 shares in the last quarter.

Some buy side analysts are also providing their Analysis on AstraZeneca PLC, where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 3 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell.

  • Zachary Reyes